Overview
The primary objective is to evaluate the impact of oliceridine versus sufentanil for perioperative analgesia on the incidence of chronic postsurgical pain (CPSP) with functional impact in patients undergoing video-assisted thoracoscopic surgery.
Description
The primary objective is to evaluate the impact of oliceridine versus sufentanil administered via patient controlled intravenous analgesia (PCIA) for perioperative analgesia on the incidence of chronic postsurgical pain (CPSP) with functional impact in patients undergoing video-assisted thoracoscopic surgery. This is a multicentre, randomised, double-blind, controlled trial enrolling 320 patients across seven Chinese tertiary centres.
Eligibility
Inclusion Criteria:
- ① Age 18-75 years, ASA physical status I-III, BMI 18-35 kg/m²;
- Scheduled for unilateral video-assisted thoracoscopic surgery (VATS) lung resection, including wedge resection, segmentectomy, lobectomy, or radical resection for lung cancer;
- Preoperative pain score \<1 on the Numeric Rating Scale (NRS);
- Ability to understand the study objectives and procedures, with voluntary informed consent obtained;
- Expected postoperative recovery in the general ward setting.
- Ability to understand the study objectives and procedures, with voluntary informed consent obtained;
- Preoperative pain score \<1 on the Numeric Rating Scale (NRS);
- Scheduled for unilateral video-assisted thoracoscopic surgery (VATS) lung resection, including wedge resection, segmentectomy, lobectomy, or radical resection for lung cancer;
Exclusion Criteria:
- ① History of chronic pain or long-term analgesic use prior to surgery;
- Previous ipsilateral thoracic surgery or conversion to thoracotomy;
- Prior neoadjuvant radiotherapy or chemotherapy;
- Severe cardiovascular or cerebrovascular disease, or hepatic/renal dysfunction (ALT/AST \>3× upper limit of normal; eGFR \<60 mL/min/1.73m²);
- Concurrent malignancy or active infection;
- diagnosed psychiatric disorders or communication barriers precluding study participation;
- Known hypersensitivity to study medications (opioids, adjuvant analgesics, anesthetics, or antiemetics);
- Pregnancy, lactation, or planned pregnancy during the study period
- Any condition deemed unsuitable for study participation by the investigator
- Pregnancy, lactation, or planned pregnancy during the study period
- Known hypersensitivity to study medications (opioids, adjuvant analgesics, anesthetics, or antiemetics);
- diagnosed psychiatric disorders or communication barriers precluding study participation;
- Concurrent malignancy or active infection;
- Severe cardiovascular or cerebrovascular disease, or hepatic/renal dysfunction (ALT/AST \>3× upper limit of normal; eGFR \<60 mL/min/1.73m²);
- Prior neoadjuvant radiotherapy or chemotherapy;
- Previous ipsilateral thoracic surgery or conversion to thoracotomy;


